Outcomes-Based Contracting Experience: Research Findings from U.S. and European Stakeholders

• DOI: 10.18553/jmcp.2017.23.10.1018
• Publication Date: 2017-09-25T08:17:07Z
• Authors: Tara Nazareth; John J. Ko; Rahul Sasane; Christian Frois; Stephen Carpenter; Sebastian Demean; Ashok Vegesna; Eric Wu; Robert P. Navarro
• Keywords: Europe; 03 medical and health sciences; 0302 clinical medicine; Drug Industry; Research; Surveys and Questionnaires; Decision Making; Humans; Pharmacy; 0305 other medical science; United States; 3. Good health

Outcomes-based contracts (OBCs), a type of risk-sharing arrangement (RSA), have emerged as promising avenue for payers to engage with pharmaceutical manufacturers share risk and improve patient access medicines via evaluation real-world outcomes.To assess the level recent OBC activity stakeholder perceptions these arrangements, well outlook future from payer manufacturer perspective in United States EU-5 (France, Germany, Italy, Spain, Kingdom).Using structured questionnaire, interviews were conducted 27 experts, including 14 U.S. payers, 5 national 8 pricing/market executives (4 U.S., 4 EU-5). We also used University Washington's Performance Based Risk-Sharing (PBRS) database other targeted publicly available information.Publicly disclosed information on OBCs understates activity, since many arrangements are confidential. Overall, interviewees generally expected that 2 3 times more would be implemented next years than previous years. Key drivers included introduction framework potentially similar Kingdom, growing sickness fund movement towards accountable care. Motivation varied markedly across markets stakeholders, operational feasibility noted significant hurdle France. Along improving health outcomes, cost financial reduction primary motivators while potential or reimbursement gains key factors manufacturers.Using direct input decision makers, this research suggests high growth is and, moderate extent, States, particularly if clear, simpler frameworks can developed.This study was funded by Novartis Pharmaceuticals. employees involved all aspects study. Vegesna Sasane employed own stock Novartis. Nazareth Ko at time Frois, Demean, Carpenter, Wu been Analysis Group, which received grant research. Navarro consulting fees his involvement Study concept design contributed Sasane, Nazareth, Wu. Navarro, Frois took lead data collection, assisted Ko, Nazareth. Data interpretation provided along Wu, Navarro. The manuscript written revised Vegesna,